Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in InventoryChange in InventoryChange in ReceivablesChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionDividends Paid - CommonDividends Paid - CommonExchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Utah Medical Products (UTMD) Gains from Investment Securities (2016 - 2025)

Utah Medical Products has reported Gains from Investment Securities over the past 15 years, most recently at $121000.0 for Q4 2025.

  • Quarterly results put Gains from Investment Securities at $121000.0 for Q4 2025, up 23.47% from a year ago — trailing twelve months through Dec 2025 was $121000.0 (up 23.47% YoY), and the annual figure for FY2025 was $121000.0, up 23.47%.
  • Gains from Investment Securities for Q4 2025 was $121000.0 at Utah Medical Products, up from $98000.0 in the prior quarter.
  • Over the last five years, Gains from Investment Securities for UTMD hit a ceiling of $121000.0 in Q4 2025 and a floor of $52000.0 in Q4 2021.
  • Median Gains from Investment Securities over the past 5 years was $84000.0 (2023), compared with a mean of $84400.0.
  • Biggest five-year swings in Gains from Investment Securities: decreased 24.64% in 2021 and later grew 28.85% in 2022.
  • Utah Medical Products' Gains from Investment Securities stood at $52000.0 in 2021, then increased by 28.85% to $67000.0 in 2022, then rose by 25.37% to $84000.0 in 2023, then increased by 16.67% to $98000.0 in 2024, then grew by 23.47% to $121000.0 in 2025.
  • The last three reported values for Gains from Investment Securities were $121000.0 (Q4 2025), $98000.0 (Q4 2024), and $84000.0 (Q4 2023) per Business Quant data.